Signs of XXXX generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.

@entity1 @entity556 @entity6343 @entity299 @entity715 @entity2120
INTRODUCTION: @entity715 is one of the most frequent adverse events after cardiac catheterization, which can be reduced by anticoagulation with unfractionated heparin (UFH) in both @entity1 and adults. Low molecular weight heparin (LMWH) might possibly offer advantages. Laboratory signs of @entity556 generation during pediatric cardiac catheterization, with unfractionated heparin (UFH) bolus or subcutaneous LMWH for @entity715 prophylaxis, were determined in a first step to investigate the potential of LMWH for antithrombotic cover. MATERIALS AND METHODS: Signs of @entity556 generation (D-dimer and @entity6343 ), anti-Xa activity and activated clotting time (ACT) were measured in 65 @entity1 with @entity299 . A total of 40 @entity1 were treated with a UFH bolus of 100 IU/kg bodyweight and, in 25 @entity1 , @entity2120 was subcutaneously administered at a dosage of 1/1.6 mg/kg bodyweight. RESULTS: The dose to plasma activity of @entity2120 was more consistent than in the UFH group. Only a slight elevation of @entity6343 was found in some @entity1 , which was a little higher in the @entity2120 group, but no difference of incidence of increased @entity6343 generation was detected between the two groups. D-dimer was elevated in three @entity1 after UFH bolus application, but no such effect was observed in any @entity1 after LMWH administration. CONCLUSIONS: Application of LMWH was equally efficacious during pediatric cardiac catheterization than UFH bolus administration, as determined by plasma levels and markers of clotting activation. In contrast to UFH bolus, no further monitoring was necessary after the application of LMWH during cardiac catheterization due to a consistent dose to plasma activity.
